Introduction
============

Of over 380 million people with diabetes worldwide, most (85-95%) have type 2 diabetes.[@ref1] Dipeptidyl peptidase-4 (DPP-4) inhibitors are a relatively new class of incretin based agents for treating type 2 diabetes. Evidence from randomised controlled trials has established that DPP-4 inhibitors reduce levels of glycated haemoglobin (HbA1c),[@ref2] [@ref3] do not affect body weight,[@ref2] pose a low risk of hypoglycaemia,[@ref4] and do not increase the risk of cardiovascular events.[@ref5] [@ref6] [@ref7] The American Diabetes Association and European Association for the Study of Diabetes have recommended this drug class as second line agents for type 2 diabetes management.[@ref8]

A recent major trial[@ref9] (SAVOR-TIMI 53) reported an increased risk of admission to hospital for heart failure (hazard ratio 1.27, 95% confidence interval 1.07 to 1.51) with the DPP-4 inhibitor saxagliptin. Although unexpected, the finding raised concern among professionals and health authorities. In 2014, the US Food and Drug Administration (FDA) requested the clinical trial data from the manufacturer to investigate the potential association between use of saxagliptin and heart failure. The FDA then recommended that "Patients should not stop taking saxagliptin and should speak with their health care professionals about any questions or concerns. Health care professionals should continue to follow the prescribing recommendations in the drug labels."[@ref10]

Subsequently, the EXAMINE trial[@ref11] testing alogliptin, and the TECOS trial[@ref12] testing sitagliptin, reported no significant effect on hospital admission for heart failure. Evidence from observational studies has been inconsistent,[@ref13] [@ref14] [@ref15] [@ref16] [@ref17] and the effect of DPP-4 inhibitors on heart failure remains controversial.

A systematic review of trials and observational studies offers an opportunity to consider the total body of evidence and potentially resolve the concern. We therefore undertook a systematic review to assess the extent to which DPP-4 inhibitors affect the risk of heart failure or hospital admission for heart failure in patients with type 2 diabetes.

Methods
=======

We followed the standards set by the meta-analysis of observational studies in epidemiology (MOOSE)[@ref18] and preferred reporting items for systematic reviews and meta-analyses (PRISMA)[@ref19] for the reporting of our study.

Eligibility criteria
--------------------

We included randomised controlled trials, non-randomised controlled trials, cohort studies, and case-control studies that compared DPP-4 inhibitors against placebo, lifestyle modification, or active antidiabetic drugs in adults with type 2 diabetes. We required follow-up for at least 12 weeks (not applicable to case-control studies), and explicit reporting of the outcome of heart failure or hospital admission for heart failure (either as raw data or adjusted effect estimates with 95% confidence intervals). We classified study designs according to recommendations by the Cochrane Non-Randomised Studies Methods Group. Trials, particularly phase III studies, reported heart failure either as a normal adverse event or a serious adverse event. For serious adverse events, admission for heart failure may have been included. We defined heart failure reported in such trials as an unspecified outcome.

Literature search
-----------------

We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) from inception to 25 June 2015. We combined both MeSH and free text terms for identifying relevant articles. An information expert (DP) developed our search strategies (web appendix 1).

We also searched ClinicalTrials.gov to identify additional eligible studies. Section 801 of the US Food and Drug Administration Amendments Act (FDAAA 801) requires responsible parties to submit summary results of clinical trials, including serious adverse events and adverse events with frequency over 5%, to this trial registry.[@ref20] [@ref21] In doing so, important information regarding heart failure can be collected. We used generic names of each drug to identify relevant studies, and limited our search to studies labelled as "completed" or "terminated," in which summary results were available.

We also contacted content experts and industry representatives, and searched for conference abstracts on the American Diabetes Association and European Association for the Study of Diabetes, for additional information.

Study process
-------------

Teams of two paired reviewers, trained in health research methods, independently screened titles, abstracts, and full texts for eligibility; assessed risk of bias; and collected data from each eligible study, using standardised, pilot tested forms, together with detailed instructions. Reviewers resolved disagreement through discussion or, if required, by adjudication by a third reviewer (XS).

Risk of bias assessment
-----------------------

We used the Cochrane Collaboration's tool[@ref22] to assess the risk of bias of randomised controlled trials. The items included random sequence generation, allocation concealment, blinding of participants, caregivers, and assessors of outcomes (that is, heart failure or hospital admission for heart failure), and adjudication of the outcomes. By assessing the risk of bias associated with blinding of patients, caregivers, and outcome assessors, we modified the instrument by removing the "unclear" option, an approach that we have previously shown to be reliable and valid.[@ref23]

We used the Newcastle-Ottawa quality assessment scale[@ref24] to assess the risk of bias of cohort studies and case-control studies. We removed the items "representativeness of the exposed cohort" and "was follow-up long enough for outcomes to occur" for cohort studies and the item "representativeness of the cases" for case-control studies because these items relate to applicability of results. We, however, added two items: the ascertainment of type 2 diabetes and the ascertainment of potential confounding factors for these both types of studies, because misclassification could result from suboptimal approaches to these issues. We planned to assess publication bias but were unable to do so owing to very low event rates.

Data collection
---------------

We collected the following information from each eligible randomised controlled trial:

1.  • General study characteristics: author name, year of publication, total number of patients randomised, number of treatment groups, length of follow-up, study phase, funding source, trial registry number, countries involved, and number of study sites

2.  • Patient characteristics: sex, age, diabetes duration, body mass index, baseline HbA1c level, and fasting plasma glucose values

3.  • Interventions: medications common to all groups (baseline treatment), details of DPP-4 inhibitors treatment and control group (eg, drug generic name, and duration of treatment)

4.  • Outcomes: the definition of heart failure, number of events, and patients included for analyses in each group, as well as adjusted data if available.

For each trial, if the initial treatment assignment was switched (eg, patients in placebo group started receiving DPP-4 inhibitors after 24 weeks), we collected the outcome data before that point. If a trial had multiple reports, we collated all data into one study.[@ref25] If a trial had both reports from ClincialTrials.gov and journal publications, we carefully checked data from these two sources for consistency. If outcome data were reported at multiple follow-up points, we used data from the longest follow-up.

For observational studies, we collected data similar to randomised controlled trials (eg, total number of patients, sex, age, diabetes duration, body mass index, baseline HbA1c). We documented, for each observational study, the definition of outcomes and sources of data for the outcomes. In addition, we documented information on:

1.  • Study design (eg, retrospective or prospective cohort study)

2.  • Data source (eg, claims data, electronic medical records)

3.  • Methods used to ascertain type 2 diabetes status (eg, International Classification of Diseases (ICD) code)

4.  • Exposures (eg, DPP-4 inhibitors, and other exposure variables)

5.  • Methods used to control confounding (eg, logistic or cox regression, and control variables).

We collected adjusted estimates and their associated 95% confidence intervals, as well as adjustment factors, in addition to raw event data and exposure time.

Data analysis
-------------

We conducted separate analyses for randomised controlled trials and observational studies. We also separately analysed the data on heart failure and hospital admission for heart failure, because those two outcomes, although sharing the same clinical and pathophysiological features, represent differential seriousness of the effect of DPP-4 inhibitors treatment on patients and society. Heart failure could be subclinical and might not be diagnosed; admission for heart failure is, however, always a clinical event and a condition important to patients and clinicians. We considered admission for heart failure as the more important outcome for patients.

For the analysis of trials, we pooled outcome data using Peto's methods because of very low event rates,[@ref26] [@ref27] and reported pooled Peto odds ratios and associated 95% confidence intervals. We examined heterogeneity among studies with the Cochrane χ^2^ test and the I^2^ statistic. We explored sources of heterogeneity with four prespecified subgroup hypotheses:

1.  • Type of control (placebo *v*active treatment; larger effect in trials with placebo control)

2.  • Length of follow-up (≤52 *v*\>52 weeks; larger effect in those with longer follow-up)

3.  • Mode of treatment (monotherapy *v*add-on or combination therapy; larger effect in those with add on or combination therapy)

4.  • Individual DPP-4 inhibitors (different DPP-4 inhibitors *v*control).

We carried out sensitivity analyses by using alternative effect measures (odds ratios *v*risk ratios), pooling methods (Peto *v*Mantel-Hanszel method), and statistical models regarding heterogeneity (random *v* fixed effects).

In the analysis of observational studies, we qualitatively summarised the data for heart failure, because of the substantial variations in the comparison (that is, type of control) and patient populations in those studies. We pooled adjusted estimates of hospital admission for heart failure from cohort and nested case-control studies using a random effects model. Although the effect measures differ for those two designs (hazard ratios for cohort studies and odds ratios for nested case-control studies), they are relative measures and the effect estimates are close when the event rate is low (\<5%).

Quality of evidence
-------------------

We used the grading of recommendations assessment, development, and evaluation (GRADE) methodology to rate quality of the evidence for heart failure and hospital admission for heart failure as high, moderate, low, or very low.[@ref28] Randomised controlled trials begin as high quality evidence, but can be rated down because of risk of bias,[@ref29] imprecision,[@ref30] inconsistency,[@ref31] indirectness,[@ref32] and publication bias.[@ref33] Observational studies begin as low quality evidence, but can be rated up for a large magnitude of effect, a dose-response gradient, or presence of plausible confounders or other biases that increase confidence in the estimated effect.[@ref34]

Patient involvement
-------------------

No patients were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on interpretation or writing up of results. There are no plans to disseminate the results of the research to study participants or the relevant patient community.

Results
=======

Of 11 440 potentially relevant reports identified, after title and abstract screening, 820 reports proved potentially eligible. On full text screening, 55 studies proved eligible, including 43 randomised controlled trials, representing 68 775 patients, reported in 77 reports[@ref9] [@ref11] [@ref12] [@ref35] [@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70] [@ref71] [@ref72] [@ref73] [@ref74] [@ref75] [@ref76] [@ref77] [@ref78] [@ref79] [@ref80] [@ref81] [@ref82] [@ref83] [@ref84] [@ref85] [@ref86] [@ref87] [@ref88] [@ref89] [@ref90] [@ref91] [@ref92] [@ref93] [@ref94] [@ref95] [@ref96] [@ref97] [@ref98] [@ref99] [@ref100] [@ref101] [@ref102] [@ref103] [@ref104] [@ref105] [@ref106] [@ref107] [@ref108] (45 from journal reports, 31 from the ClinicalTrials.gov website, and one conference abstract) and 12 observational studies,[@ref13] [@ref14] [@ref15] [@ref16] [@ref17] [@ref109] [@ref110] [@ref111] [@ref112] [@ref113] [@ref114] [@ref115] involving 1 777 358 patients, reported in nine cohort studies and three nested case-control studies (nine from journal reports, one from a trial registry, and two conference abstracts; fig 1[](#f1){ref-type="fig"}). Two cohort studies[@ref15] [@ref116] analysed patient data from the same claims database, one presenting a subpopulation of the other; we included only the larger cohort study.[@ref15]

![**Fig 1** Flowchart of article selection](lili029738.f1_default){#f1}

Evidence from randomised controlled trials
------------------------------------------

### Trials reporting heart failure

Of the 43 randomised controlled trials, 38 reported heart failure, of which 33 (87%) were international studies, and 35 (92%) were clearly labelled as phase III trials. These 38 trials enrolled 109-2789 patients (total n=31 680; mean age range 49.7-72.6 years, mean body mass index 24.0-32.8, mean baseline HbA1c 7.1-9.9%, mean fasting plasma glucose 7.7-11.1 mmol/L, and mean duration of diabetes 1.7-17.5 years; table 1[](#tbl1){ref-type="table"}). Nine trials used DPP-4 inhibitors as monotherapy, 27 as add-on or combination therapy, and two as both monotherapy and combination therapy. Length of follow-up ranged from 12 to 206 weeks (median 52; table 2[](#tbl2){ref-type="table"}).

###### 

Characteristics of included randomised controlled trials

  Author (year)                                               International study   No of countries involved   No of study sites   Study phase   Total No of patients randomised   Length of follow-up (weeks)   Male patients (No, %)   Mean age (years)   Mean body mass index   Mean HbA1c (%)   Mean FPG (mmol/L)   Mean diabetes duration (years)
  ----------------------------------------------------------- --------------------- -------------------------- ------------------- ------------- --------------------------------- ----------------------------- ----------------------- ------------------ ---------------------- ---------------- ------------------- --------------------------------
  **Trials reporting heart failure**                                                                                                                                                                                                                                                                                    
  Arjona Ferreira (2013)a^35, 36^                             Yes                   NR                         NR                  III           426                               54                            158 (57)                64.5               26.8                   7.8              8.1                 10.4
  Arjona Ferreira (2013)b^37, 38^                             Yes                   12                         31                  III           129                               54                            77 (59.7)               59.5               26.8                   7.8              9.0                 17.5\*
  Bosi (2011)^39^                                             Yes                   NR                         NR                  III           803                               52                            414 (51.6)              55.1               31.5                   8.2              9.0                 7.2
  Ferrannini (2009)^40^                                       Yes                   24                         402                 III           2789                              52                            1490 (53.4)             57.5               31.8                   7.3              9.2                 5.7
  Fonseca (2013)^41^                                          Yes                   12                         58                  III           313                               26                            195 (62.3)              56.0               29.9                   9.8              9.8                 NR
  Garber (2007)^42^                                           Yes                   2                          123                 III           463                               24                            199 (50)                54.0               32.4                   8.7              10.1                4.7
  Henry (2014)^43, 44^                                        NR                    NR                         NR                  III           1615                              54                            912 (56.5)              NR                 30.9                   8.8              10.0                7.9
  Iwamoto (2010)^45, 46^                                      Yes                   1                          97                  II            363                               12                            224 (61.7)              59.8               24.5                   7.6              8.2                 5.4
  NCT00094770 (2009)^47, 48, 49^                              Yes                   NR                         173                 III           1172                              104                           694 (59.2)              56.7               31.2                   7.7              9.2                 6.4
  NCT00103857 (2009)^50, 51^                                  Yes                   NR                         140                 III           1091                              104                           539 (49.4)              53.5               NR                     8.8              11.1                NR
  NCT00121641 (2011)^52, 53^                                  NR                    6                          135                 III           403                               206                           204 (50.9)              53.5               31.7                   7.9              9.7                 2.6
  NCT00121667 (2011)^54, 55^                                  Yes                   9                          154                 III           745                               206                           377 (50.7)              54.6               31.4                   NR               NR                  NR
  NCT00286442 (2011)^56, 57^                                  Yes                   15                         115                 III           527                               26                            265 (50.3)              54.8               32.0                   7.9              9.5                 6.0
  NCT00286468 (2011)^58, 59^                                  Yes                   15                         125                 III           585                               26                            261 (52.2)              56.6               30.1                   NR               NR                  7.7
  NCT00295633 (2009)^60, 61, 62^                              Yes                   8                          133                 III           565                               76                            643 (49.2)              52.0               30.2                   9.5              11.1                1.7
  NCT00327015 (2009)^63, 64, 65^                              Yes                   13                         211                 III           1309                              24                            643 (49.2)              52.0               30.2                   9.5              11.1                1.7
  NCT00395343 (2009)^66, 67^                                  Yes                   24                         100                 III           641                               24                            326 (50.9)              57.8               31.0                   8.7              9.8                 12.5
  NCT00482729 (2009)^68, 69, 70^                              Yes                   2                          229                 III           1250                              44                            708 (56.8)              49.7               NR                     9.9              NR                  NR
  NCT00575588 (2010)^71, 72, 73^                              Yes                   11                         130                 III           858                               104                           444 (51.7)              57.5               31.4                   7.7              9.0                 5.4
  NCT00614939 (2010)^74, 75, 76^                              Yes                   13                         75                  III           170                               52                            73 (42.9)               66.5               30.7                   8.3              9.9                 16.7
  NCT00622284 (2011)^77, 78^                                  Yes                   16                         209                 III           1560                              104                           933 (60.2)              56.6               30.2                   7.7              9.1                 715 (47.1)†
  NCT00642278 (2013)^79, 80^                                  Yes                   13                         85                  II            451                               12                            236 (52.3)              52.9               31.5                   7.8              9.0                 NR
  NCT00707993 (2013)^81, 82^                                  Yes                   15                         110                 III           441                               54                            198 (44.9)              69.9               29.8                   7.5              8.1                 6.1
  NCT00757588 (2011)^83, 84^                                  Yes                   10                         72                  III           457                               24                            188 (41.3)              57.2               32.3                   8.7              9.6                 11.9
  NCT00798161 (2011)^85, 86^                                  Yes                   14                         133                 III           791                               24                            426 (53.9)              55.3               29.1                   8.7              10.9                562 (74.3)†
  NCT00838903 (2014)^87, 88^                                  Yes                   10                         289                 III           1049                              164                           482 (47.6)              54.5               32.6                   8.1              9.2                 6.0
  NCT00856284 (2013)^89, 90^                                  Yes                   32                         310                 III           2639                              104                           1312 (49.7)             55.4               31.2                   7.6              NR                  5.5
  NCT00954447 (2012)^91^                                      Yes                   19                         167                 III           1263                              52                            658 (52.2)              60.0               31.0                   8.3              8.3                 NR
  NCT01006603 (2013)^92^                                      Yes                   13                         152                 IV            720                               52                            445 (61.8)              72.6               NR                     NR               NR                  NR
  NCT01189890 (2013)^93^                                      Yes                   NR                         NR                  III           480                               30                            202 (42.1)              70.7               NR                     7.8              9.4                 NR
  NCT01263483 (2011)^94, 95^                                  No                    1                          31                  II and III    230                               12                            142 (61.7)              62.1               24.0                   8.0              NR                  7.8
  NCT01289990 (2014)^96^                                      Yes                   19                         243                 III           2700                              76                            1492 (55.3)             55.6               NR                     NR               NR                  NR
  Pratley (2009)^97, 98^                                      Yes                   14                         125                 III           493                               26                            287 (58.2)              55.4               32.8                   8.0              NR                  7.6
  Pratley (2014)^99^                                          Yes                   13                         198                 III           784                               26                            374 (47.7)              53.5               30.7                   NR               NR                  4.0
  Rosenstock (2006)^100^                                      Yes                   17                         NR                  III           353                               24                            196 (55.5)              56.3               31.5                   8.0              9.2                 NR
  Rosenstock (2010)^101^                                      Yes                   23                         268                 III           655                               26                            320 (48.9)              52.6               31.1                   8.8              10.6                3.2
  Seino (2012)^102^                                           No                    1                          30                  III           288                               12                            198 (68.8)              52.6               25.9                   8.0              NR                  6.3
  Yang (2015)^103^                                            No                    1                          25                  III           109                               24                            57 (54.3)               56.2               25.0                   7.1              7.7                 3.6
  **Trials reporting hospital admission for heart failure**                                                                                                                                                                                                                                                             
  Green (2015) (TECOS)^12^                                    Yes                   38                         673                 III           14  735                           156‡                          10 374 (70.7)           65.5               30.2                   7.2              NR                  11.6
  Krum (2014) (VIVIDD)^104^                                   NR                    NR                         NR                  NR            253                               52                            NR                      63                 NR                     7.8              NR                  NR
  Laakso (2015)^105^                                          Yes                   9                          52                  III           235                               52                            149 (63.4)              66.6               NR                     8.1              NR                  NR
  Scirica (2013) (SAVOR-TIMI 53)^9, 106^                      Yes                   26                         788                 IV            16  492                           109‡                          11 037 (66.9)           65.0               31.1                   NR               8.7                 10.3\*
  Zannad (2015) (EXAMINE)^11, 107, 108^                       Yes                   49                         898                 III           5380                              76‡                           3651 (67.9)             60.9               29.5                   NR               NR                  9.2

FPG=fasting plasma glucose; NR=not reported.

\*Median diabetes duration (years).

†No (%) of patients with no more than five years' duration.

‡Median follow-up time (weeks).

###### 

Interventions tested and event rates in randomised controlled trials

  Author (year)                                               Drug treatments used across groups                                                      DPP-4 inhibitors                   Control               Duration of treatment (weeks)              
  ----------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------ --------------- --------------------- ------------------------------- ---------- -------
  **Trials reporting heart failure**                                                                                                                                                                                                                      
  Arjona Ferreira (2013)a^35, 36^                             None                                                                                    Sitagliptin        0/210                                 Glipizide                       4/212      54
  Arjona Ferreira (2013)b^37, 38^                             None                                                                                    Sitagliptin        2/64                                  Glipizide                       2/65       54
  Bosi (2011)^39^                                             Metformin, and pioglitazone 30 mg                                                       Alogliptin         2/404                                 Add-on pioglitazone 15 mg       1/399      52
  Ferrannini (2009)^40^                                       Metformin                                                                               Vildagliptin       2/1389                                Glimepiride                     2/1383     52
  Fonseca (2013)^41^                                          Metformin and pioglitazone                                                              Sitagliptin        0/157                                 Placebo                         0/156      26
  Garber (2007)^42^                                           Pioglitazone                                                                            Vildagliptin       1/304                                 Placebo                         1/158      24
  Henry (2014)^43, 44^                                        Pioglitazone                                                                            Sitagliptin        2/691                                 No additional drugs             0/693      54
  Iwamoto (2010)^45, 46^                                      None                                                                                    Sitagliptin        1/290                                 Placebo                         0/73       12
  NCT00094770 (2009)^47, 48, 49^                              Metformin                                                                               Sitagliptin        2/588                                 Glipizide                       1/584      104
  NCT00103857 (2009)^50, 51^                                  Metformin                                                                               Sitagliptin        1/372                                 No additional drugs             0/364      104
  NCT00121641 (2011)^52, 53^                                  None                                                                                    Saxagliptin        1/306                                 Placebo                         0/95       206
  NCT00121667 (2011)^54, 55^                                  Metformin                                                                               Saxagliptin        3/564                                 Placebo                         2/179      206
  NCT00286442 (2011)^56, 57^                                  Metformin                                                                               Alogliptin         1/423                                 Placebo                         0/104      26
  NCT00286468 (2011)^58, 59^                                  Glyburide                                                                               Alogliptin         1/401                                 Placebo                         0/99       26
  NCT00295633 (2009)^60, 61, 62^                              TZD                                                                                     Saxagliptin        0/381                                 Placebo                         1/184      76
  NCT00327015 (2009)^63, 64, 65^                              Metformin                                                                               Saxagliptin        0/643                                 No additional drugs             2/328      24
  NCT00395343 (2009)^66, 67^                                  Insulin with or without metformin                                                       Sitagliptin        0/322                                 Placebo                         2/319      24
  NCT00482729 (2009)^68, 69, 70^                              Metformin                                                                               Sitagliptin        1/625                                 No additional drugs             0/621      44
  NCT00575588 (2010)^71, 72, 73^                              Metformin                                                                               Saxagliptin        1/428                                 Glipizide                       1/430      104
  NCT00614939 (2010)^74, 75, 76^                              OADs and/or insulin                                                                     Saxagliptin        1/85                                  Placebo                         0/85       52
  NCT00622284 (2011)^77, 78^                                  Metformin                                                                               Linagliptin        3/776                                 Glimepiride                     2/775      104
  NCT00642278 (2013)^79, 80^                                  Metformin                                                                               Sitagliptin        0/65                                  Placebo                         0/65       12
  Sitagliptin                                                 0/65                                                                                                       Canagliflozin   1/321                                                            
  NCT00707993 (2013)^81, 82^                                  None                                                                                    Alogliptin         1/222                                 Glipizide                       1/219      52
  NCT00757588 (2011)^83, 84^                                  Insulin with or without metformin                                                       Saxagliptin        2/304                                 Placebo                         0/151      24
  NCT00798161 (2011)^85, 86^                                  None                                                                                    Linagliptin        0/142                                 Placebo                         0/72       24
  Metformin                                                   Linagliptin                                                                             1/286                              No additional drugs   0/291                                      
  NCT00838903 (2014)^87, 88^                                  Metformin                                                                               Sitagliptin        1/302                                 Glimepiride                     1/307      156
  Sitagliptin                                                 1/302                                                                                                      Placebo         0/101                                                            
  NCT00856284 (2013)^89, 90^                                  Metformin                                                                               Alogliptin         3/1751                                Glipizide                       1/878      104
  NCT00954447 (2012)^91^                                      Basal insulin and/or OADs                                                               Linagliptin        3/631                                 Placebo                         2/630      52
  NCT01006603 (2013)^92^                                      None                                                                                    Saxagliptin        1/359                                 Glimepiride                     3/359      52
  NCT01189890 (2013)^93^                                      None                                                                                    Sitagliptin        0/241                                 Glimepiride                     1/236      30
  NCT01263483 (2011)^94, 95^                                  Voglibose                                                                               Alogliptin         0/155                                 Placebo                         1/75       12
  NCT01289990 (2014)^96^                                      None                                                                                    Sitagliptin        1/223                                 Placebo                         0/223      76
  Sitagliptin                                                 1/223                                                                                                      Empagliflozin   0/453                                                            
  Pratley (2009)^97, 98^                                      Pioglitazone or pioglitazone, plus metformin or SU                                      Alogliptin         3/397                                 Placebo                         0/97       26
  Pratley (2014)^99^                                          None                                                                                    Alogliptin         0/222                                 Placebo                         0/106      26
  Metformin                                                   Alogliptin                                                                              0/220                              No additional drugs   0/220                                      
  Rosenstock (2006)^100^                                      Pioglitazone                                                                            Sitagliptin        0/175                                 Placebo                         0/178      24
  Rosenstock (2010)^101^                                      Pioglitazone                                                                            Alogliptin         0/327                                 No additional drugs             0/163      26
  Seino (2012)^102^                                           Metformin                                                                               Alogliptin         1/188                                 Placebo                         0/100      12
  Yang (2015)^103^                                            None                                                                                    Anagliptin         0/68                                  Placebo                         1/40       24
  **Trials reporting hospital admission for heart failure**                                                                                                                                                                                               
  Green (2015) (TECOS)^12^                                    One or two OADs (metformin, pioglitazone, or SU) or insulin with or without metformin   Sitagliptin        228/7332                              Placebo                         229/7339   156\*
  Krum (2014) (VIVIDD)^104^                                   Standard diabetes treatment                                                             Vildagliptin       13/128                                Placebo                         10/124     52
  Laakso (2015)^105^                                          None                                                                                    Linagliptin        7/113                                 Placebo or glimepiride          6/120      52
  Scirica (2013) (SAVOR-TIMI 53)^9, 106^                      Antihyperglycaemic drugs                                                                Saxagliptin        289/8280                              Placebo                         228/8212   109\*
  Zannad (2015) (EXAMINE)^11, 107, 108^                       Standard of care treatment for type 2 diabetes mellitus                                 Alogliptin         85/2701                               Placebo                         79/2679    78\*

BG=biguanide; TZD=thiazolidinedione; OADs=oral antidiabetic drugs; SU=sulfonylurea.

\*Median treatment time (weeks).

All 38 trials were industry funded. Most (n=24) were identified from ClinicalTrials.gov, of which four[@ref91] [@ref92] [@ref93] [@ref96] have not been published in a peer reviewed journal. Because of the limited information in the trial registry, we were unable to adequately assess the risk of bias for these four trials. On the basis of the information we collected, 16 (42%) trials adequately generated their randomisation sequence; 11 (29%) adequately concealed allocation; all trials blinded patients, caregivers, and outcome assessors; eight (21%) adjudicated heart failure events; and four (11%) used blinded assessors to adjudicate heart failure (web appendix 2). The treatment groups of each included trial were generally balanced with respect to demographic and clinical characteristics.

### Effects on heart failure

The 38 trials reported 75 heart failure events occurring in 28 292 patients who were treated with at least one drug (raw event rate 0.27%). The definition of heart failure was available in only one trial[@ref37]; 33 (87%) trials reported heart failure as serious adverse events. The pooling of data from these trials showed no significant difference in the risk of heart failure between DPP-4 inhibitors treatment and control. Event rates were 0.27% for DPP-4 inhibitors versus 0.26% for controls (odds ratio 0.97 (95% confidence interval 0.61 to 1.56), I^2^=0%; risk difference 2 fewer (19 fewer to 28 more) events per 1000 patients with type 2 diabetes over five years; fig 2[](#f2){ref-type="fig"} and table 3[](#tbl3){ref-type="table"}). We rated the quality of evidence as low because of risk of bias and imprecision (table 3[](#tbl3){ref-type="table"}).

![**Fig 2** Risk of heart failure in patients with type 2 diabetes who received DPP-4 inhibitors versus control from randomised controlled trials](lili029738.f2_default){#f2}

###### 

GRADE evidence profile of DPP-4 inhibitors and risk of heart failure in type 2 diabetes

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Quality assessment                                                                     Summary of findings      Quality of evidence                                                                                                                                                                                                                            
  ------------------------------------------ ------------------------------------------- ------------------------ ------------------------ ----------------------------------------------------------------------------- ------------ -- ------------------- ------------------- -------------------------------- -------------- ------------------------------- -------------------------------------
  **Heart failure**                                                                                                                                                                                                                                                                                                                                              

  28 292 (38), 12-206 weeks                  Serious limitation, due to risk of bias\*   No serious limitations   No serious limitations   Serious limitation, confidence interval includes important benefit and harm   Undetected      33/12 591 (0.26%)   42/15 701 (0.27%)   Odds ratio 0.97 (0.61 to 1.56)   50 per 1000†   2 fewer (19 fewer to 28 more)   ⊕⊕ΟΟ\
                                                                                                                                                                                                                                                                                                                                                                 **Low**\
                                                                                                                                                                                                                                                                                                                                                                 due to risk of bias and imprecision

  **Hospital admission for heart failure**                                                                                                                                                                                                                                                                                                                       

  37 028 (5), 1-3 years                      No serious limitations                      No serious limitations   No serious limitations   Serious limitation, confidence interval includes no harm and important harm   Undetected      552/18 474 (3%)     622/18 554 (3.4%)   Odds ratio 1.13 (1.00 to 1.26)   60 per 1000‡   8 more (0 more to 16 more)      ⊕⊕⊕Ο\
                                                                                                                                                                                                                                                                                                                                                                 **Moderate** due to imprecision
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Most trials had unclear risk of bias on random sequence generation and allocation concealment (web appendix 2), and the follow-up (median of 52 weeks) was not long enough for heart failure to occur in patients at low risk of cardiovascular disease.

†Baseline risk estimate for heart failure in a five year time frame comes from the control arm of the cohort study we identified to best represent our target population (Kannan 2015^111^), with 528 events of heart failure in 13 185 participants (4.0%) at four year follow-up across the control and intervention arms.

‡Baseline risk estimate for hospital admission for heart failure in a five year time frame comes from control arms of the five trials we identified to best represent our target population (fig 3[](#f3){ref-type="fig"}) with 552 events in 18 474 participants (30 per 1000) over a 2.5 year follow-up period, in the absence of observational studies providing more credible baseline risk estimates.

§Units are no of events per 1000 patients with type 2 diabetes mellitus over a five year time frame.

The subgroup analysis by type of control (placebo *v* active drugs) showed no difference in treatment effects (interaction P=0.57; comparison with placebo, odds ratio 1.17 (95% confidence interval 0.58 to 2.33); comparison with active drugs, 0.89 (0.47 to 1.66); fig A in web appendix 3). The subgroup analyses of the other three prespecified hypotheses showed no difference in treatment effects (figs B-D in appendix 3). Sensitivity analysis using alternative effect measures, statistical methods, and analysis models did not show important changes in pooled effects (figs E-G in web appendix 3).

### Trials reporting hospital admission for heart failure

We included three large trials[@ref9] [@ref11] [@ref12] (SAVOR-TIMI 53, EXAMINE, and TECOS) and two small trials[@ref104] [@ref105] reporting hospital admission for heart failure; all were designed to assess the cardiovascular safety of DPP-4 inhibitors compared with placebo (table 1[](#tbl1){ref-type="table"}). The SAVOR-TIMI 53 trial investigated saxagliptin in patients with diabetes who had a renal impairment and cardiovascular disease or multiple risk factors for vascular disease. The EXAMINE trial recruited patients receiving alogliptin with type 2 diabetes and a recent acute coronary syndrome. The TECOS trial examined sitagliptin in patients with type 2 diabetes and cardiovascular disease. In addition, one small trial[@ref104] assessed vildagliptin in patients with type 2 diabetes as well as heart failure and a left ventricular ejection fraction less than 40%; the other small trial[@ref105] assessed linagliptin in patients with type 2 diabetes with moderate to severe renal impairment.

All three large trials were international studies. The median length of follow-up ranged from 76 to 156 weeks (table 1). Those trials enrolled 5380-16 492 patients (total n=36 607; mean age range 60.9-65.5 years, mean body mass index 29.5-31.1, and duration of diabetes 9.2-11.6 years). The two small trials followed up patients for 52 weeks; mean age ranged from 63 to 66.6 years and mean HbA1c levels ranged from 7.8% to 8.1%.

All trials, but one[@ref104] (which had unclear details because it was presented as an abstract), adequately generated their randomisation sequence and adequately concealed allocation; all trials blinded patients, caregivers, outcome assessors, and centrally adjudicated hospital admission for heart failure outcome through a clinical events classification committee who were blinded to treatment allocation. All trials were funded by industry (web appendix 2).

### Effects on hospital admission for heart failure

All five trials[@ref9] [@ref11] [@ref12] [@ref104] [@ref105] reported unadjusted rates of hospital admission for heart failure. Overall, 1174 events of admission for heart failure occurred in 37 028 patients (raw event rate 3.4% for DPP-4 inhibitors *v*3.0% for controls; table 3[](#tbl3){ref-type="table"}). Pooling across trials showed a borderline increase in the risk of hospital admission for heart failure in patients with type 2 diabetes using DPP-4 inhibitors versus control (odds ratio 1.13 (95% confidence interval 1.00 to 1.26), I^2^=0%; risk difference 8 more (0 more to 16 more) per 1000 patients with type 2 diabetes over five years; fig 3[](#f3){ref-type="fig"} and table 3[](#tbl3){ref-type="table"}). We rated the quality of evidence as moderate due to imprecision (table 3[](#tbl3){ref-type="table"}). Sensitivity analysis by use of alternative effect measures, statistical methods, and analysis models did not show important changes in the pooled effects (figs H-J in web appendix 3).

![**Fig 3** Risk of hospital admission for heart failure in patients with type 2 diabetes who received DPP-4 inhibitors versus control from randomised controlled trials](lili029738.f3_default){#f3}

Evidence from observational studies
-----------------------------------

Of 12 observational studies, four[@ref109] [@ref110] [@ref111] [@ref112] reported heart failure, and eight[@ref13] [@ref14] [@ref15] [@ref16] [@ref17] [@ref113] [@ref114] [@ref115] reported hospital admission for heart failure; nine[@ref13] [@ref14] [@ref15] [@ref109] [@ref110] [@ref111] [@ref113] [@ref114] [@ref115] were cohort studies and the other three[@ref16] [@ref17] [@ref112] were nested case-control studies (fig 1[](#f1){ref-type="fig"}).

### Observational studies reporting heart failure

Of the four studies reporting heart failure, two prospective cohort studies[@ref109] [@ref110] compared DPP-4 inhibitors versus sulfonylureas and sitagliptin versus sulfonylureas. One retrospective cohort study[@ref111] assessed DPP-4 inhibitors versus sulfonylureas and reported the findings from the subgroup of DPP-4 inhibitors. Finally, one nested case-control study[@ref112] using claims data investigated use of sitagliptin versus no use in patients admitted to hospital for acute coronary syndrome (table 4[](#tbl4){ref-type="table"} and table 5[](#tbl5){ref-type="table"}). Sample sizes ranged from 616 to 13 185, and the mean or median length of follow-up ranged from one to four years. Enrolled patients had a mean or median age ranging from 55 to 65.8 years. None of the studies explicitly defined provided diagnostic criteria for heart failure.

###### 

Characteristics of included observational studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                                                Study design                 Data source                  Countries     Funding                      Total No of patients   Follow-up (years)   Male patients (No (%))   Mean age (years)   Mean body mass index   Mean HbA1c (%)   Mean FPG (mmol/L)   Mean diabetes duration (years)   CVD at baseline
  ------------------------------------------------------------ ---------------------------- ---------------------------- ------------- ---------------------------- ---------------------- ------------------- ------------------------ ------------------ ---------------------- ---------------- ------------------- -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  **Studies reporting heart failure**                                                                                                                                                                                                                                                                                                                   

  Gitt (2013)^109^                                             Prospective cohort study     Registry data                Germany       Private for-profit funding   616                    1                   3097 (49.8)              65.8†              NR                     7.3†             7.7†                4.9†                             Included patients had CVD or had no CVD at baseline

  NCT01357135 (2014)^110^                                      Prospective cohort study     Electronic medical records   France        Private for-profit funding   3453                   3                   2004 (58.0)              63.5               NR                     NR               NR                  NR                               NR

  Kannan (2015)\*^, 111^                                       Retrospective cohort study   Electronic health records    USA           No funding                   13 185                 4†                  7827 (54.6)              60.6               32.6†                  NR               NR                  NR                               Included patients had no history of CVD or congestive heart failure at baseline

  Eurich (2014)^112^                                           Nested case-control study    Claims data                  USA           NR                           5027                   NA                  3268 (65)                55                 NR                     NR               NR                  NR                               Included patients had no history of heart failure in the 3 years before admission to hospital for an acute coronary syndrome event

  **Studies reporting hospital admission for heart failure**                                                                                                                                                                                                                                                                                            

  Fadini (2015)^13^                                            Retrospective cohort study   Registry data                Italy         Public funding               127 555                2.6                 66 201 (51.9)            67.0               NR                     NR               NR                  NR                               Included patients had CVD or no CVD at baseline

  Fu (2015)^14^                                                Retrospective cohort study   Claims data                  USA           NR                           218 556                0.5                 NR                       NR                 NR                     NR               NR                  NR                               Included patients had CVD or no CVD at baseline

  Seong (2015)^113^                                            Retrospective cohort study   Claims data                  South Korea   No funding                   349 476                0.6                 191 167 (54.7)           58.3               NR                     NR               NR                  NR                               Included patients had no history of CVD within 2.5 years before cohort entry

  Suh (2015)^114^                                              Retrospective cohort study   Claims data                  South Korea   NR                           935 519                0.9                 518 614 (55.4)           59.4               NR                     NR               NR                  NR                               NR

  Velez\                                                       Retrospective cohort study   Electronic medical records   USA           Public funding               4224                   2.0†                2265 (53.6)              60.8               NR                     8.0              NR                  2.5                              Included patients had CVD or no CVD at baseline
  (2015)\*^, 115^                                                                                                                                                                                                                                                                                                                                       

  Wang (2014)^15^                                              Retrospective cohort study   Claims data                  Taiwan        Public funding               16 576                 1.5†                8615 (52.0)              64.3               NR                     NR               NR                  8.6                              Included patients had CVD or no CVD at baseline

  Weir (2014)^16^                                              Nested case-control study    Claims data                  USA           NR                           45 434                 NA                  27 013 (59.5)            54.6               NR                     7.5              NR                  NR                               Included patients were recently diagnosed with heart failure

  Yu (2015)\*^, 17^                                            Nested case-control study    Electronic medical records   UK            Public funding               57 737                 NA                  32 795 (56.8)            61.6               NR                     NR               NR                  2.3                              Included patients had CVD or no CVD at baseline
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FPG=fasting plasma glucose; CVD=cardiovascular disease; NR=not reported; NA=not applicable.

\*Three studies accessed incretin agents (both glucagon-like peptide 1 receptor agonists and DPP-4 inhibitors) and the risk of heart failure, so the data above were the characteristics of total patients included.

†Median value.

###### 

Exposures, outcomes, and results of included observational studies

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)                                                Exposure of interest                                                                                                   Control group                             No of events or cases   Total no of analysed patients    Adjusted estimates (95% CI)                                                                                                  Adjusted covariate
  ------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------- ----------------------------------------- ----------------------- -------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Studies reporting heart failure**                                                                                                                                                                                                                                                                                                                                                                                 

  Eurich (2014)^112^                                           Sitagliptin use                                                                                                        No use                                    457                     5027                             OR 0.75 (0.38 to 1.46)                                                                                                       Demographics, clinical and laboratory data, pharmacy claims, healthcare use and propensity scores (conditional probability of being treated with metformin or sulfonylurea or insulin or sitagliptin)

  Kannan (2015)^111^                                           DPP-4 inhibitors (combined with metformin)                                                                             Sulfonylureas (combined with metformin)   528\*                   13 185 (55 110 person years)\*   HR 1.10 (1.04 to 1.17)                                                                                                       Age, sex, race, body mass index, number of encounters, median household income, smoking status, systolic and diastolic blood pressure, hypertension, dyslipidaemia, cerebral vascular event, presence of neuropathy, retinopathy, dementia, chronic obstructive pulmonary disease, cancer, atrial fibrillation, antihypertensive drugs, lipid lowering agents, antiplatelet agents, and propensity for being on metformin and sulfonylureas at baseline, lipid profile, estimated glomerular filtration rate

  Gitt (2013)^109^                                             DPP-4 inhibitors                                                                                                       Sulfonylureas                             11                      616                              NR                                                                                                                           NR

  NCT01357135 (2014)^110^                                      Sitagliptin (combined with metformin)                                                                                  Sulfonylureas (combined with metformin)   2                       2607                             NR                                                                                                                           NR

  **Studies reporting hospital admission for heart failure**                                                                                                                                                                                                                                                                                                                                                          

  Fadini (2015)^13^                                            DPP-4 inhibitors                                                                                                       Sulfonylureas                             1181                    110 757                          HR 0.78 (0.62 to 0.97)                                                                                                       Age, sex, use of certain medications (drugs for hypertension, dyslipidaemia, chronic obstructive pulmonary disease, non-steroidal anti-inflammatory drugs, and antiplatelet drugs), presence of previous hospital admissions, Charlson index level grouped into three categories, previous use of oral glucose lowering drugs, cotreatment with metformin, and adherence level categorised on the basis of the medication possession ratio (MPR (%); \<80% *v* ≥80%)

  Fu (2015)^14^                                                DPP-4 inhibitors                                                                                                       Sulfonylureas                             495                     218 556                          No CVD at baseline:\                                                                                                         Adjusted covariates of Cox proportional hazard models were not stated explicitly; each comparison consisted of patients matched 1:1 on a propensity score based on demographics, general clinical characteristics, and hospital admission for heart failure risk factors from one year before baseline; analyses were stratified by presence of CVD
                                                                                                                                                                                                                                                                                         HR 0.59 (0.38 to 0.89); CVD at baseline:\                                                                                    
                                                                                                                                                                                                                                                                                         0.95 (0.78 to 1.15)                                                                                                          

  Seong (2015)^113^                                            DPP-4 inhibitors                                                                                                       Sulfonylureas and pioglitazone            212                     349 476 (211 959 person years)   DPP-4 inhibitors *v*sulfonylureas: adjusted HR 0.93 (0.62 to 1.41); DPP-4 inhibitors *v* pioglitazone: 0.21 (0.15 to 0.28)   Adjusted factors included age, sex, duration of diabetes at baseline; comorbidities in year before the index date (microvascular complications of diabetes (retinopathy, neuropathy, or nephropathy), peripheral vascular disease, hypertension, and dyslipidemia), and associated Charlson score; diabetes related hospital admission and total number of hypoglycaemic drug classes used in year before the index date; and use of the following drug classes in year before the index date: hypoglycaemic, lipid lowering, antihypertensive, antiplatelet (drug names not listed here)

  Suh (2015)^114^                                              DPP-4 inhibitors                                                                                                       Pioglitazone                              998                     935 519                          Sitagliptin *v*pioglitazone: adjusted HR 0.97 (0.80 to 1.16); vildagliptin *v*pioglitazone: 1.22 (0.99 to 1.50)              Age and sex

  Velez (2015)^115^                                            DPP-4 inhibitors                                                                                                       Control (no details)                      127                     3987                             HR 0.58 (0.38, 0.88)                                                                                                         Propensity score, number of antidiabetic drugs, duration of diabetes, baseline beta blocker use, and use of angiotensin converting enzyme inhibitor or angiotensin receptor blocker

  Wang (2014)^15^                                              Sitagliptin use                                                                                                        No use                                    614                     16 576                           HR 1.21 (1.04 to 1.42)                                                                                                       Adjusted covariates of Cox proportional hazard models were not stated explicitly; potential confounding were mitigated by the propensity score matching approach, and covariates included age, sex, duration of diabetes, antidiabetic drugs used, comorbidities, and outpatient visit

  Weir (2014)^16^                                              Sitagliptin use                                                                                                        No use                                    824                     9062                             OR 1.84 (1.16 to 2.92)                                                                                                       Demographics (age, sex, and socioeconomic status), most recent clinical laboratory data (HbA1c, low and high density lipoprotein cholesterol, triglycerides, estimated glomerular filtration rate, albuminuria, and haemoglobin concentrations), history of CVD (ischaemic heart disease, myocardial infarction, dyslipidaemia, hypertension, arrhythmia, and valve disease), and prescription drug use (antiplatelet drugs, anticoagulants, statins, calcium channel blockers, β blockers, angiotensin converting enzyme inhibitors, renin inhibitors, diuretics, and nitrates)

  Yu (2015)^17^                                                DPP-4 inhibitors (sitagliptin, vildagliptin, and saxagliptin, alone or in combination with other antidiabetic drugs)   Other oral antidiabetic drugs             1118\*                  18 744\*                         OR 0.88 (0.63 to 1.22)                                                                                                       Sex, body mass index, excessive alcohol use, smoking status, HbA1c level, comorbidities (neuropathy, renal disease, retinopathy, atrial fibrillation, cancer (other than non-melanoma skin cancer), chronic obstructive pulmonary disease, coronary artery disease, dyslipidaemia, hypertension, previous myocardial infarction, peripheral arteriopathy, previous coronary revascularisation, peripheral vascular disease, and previous stroke), number of prescriptions, number of physician visits, and use of the following drugs in the year before cohort entry: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, calcium channel blockers, diuretics, fibrates, statins, aspirin, and other non-steroidal anti-inflammatory drugs
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NR=not reported; HR=hazard ratio; OR=odds ratio; CVD=cardiovascular disease.

\*These two studies accessed incretin drugs and the risk of heart failure, and data of events/cases and total number of analysed patients regarding glucagon-like peptide 1 receptor agonists and DPP-4 inhibitors were not reported separately, so the data above were of total study patients.

Four studies used registry data, electronic health or medical records, or claims data for their analyses. Patients with type 2 diabetes were ascertained by physicians in one prospective cohort study[@ref109] or by ICD-9 Clinical Modification (CM) codes in one nested case-control study[@ref112]; the other two cohort studies[@ref110] [@ref111] did not explicitly report the ascertainment of type 2 diabetes. None of these studies mentioned the ascertainment of exposure to DPP-4 inhibitors agents and other confounding variables; the accuracy of ascertaining exposure and confounding factors was unclear. Of these three cohort studies, only one[@ref111] demonstrated that the outcome of interest was not present at start of study, and mentioned the method used to assess the outcome of interest. Of these four studies, two[@ref111] [@ref112] controlled for the effect of confounding factors (web appendices 4 and 5).

### Effects on heart failure

All three cohort studies[@ref109] [@ref110] [@ref111] reported unadjusted rates of heart failure, involving 541 events among 16 408 patients (raw event rate 3.3%). Because of the heterogeneous and indirect nature of the identified evidence---with substantial variations in comparisons and types of patients---we did not pool data across studies. The outcome information is presented in table 5[](#tbl5){ref-type="table"}.

One retrospective cohort study[@ref111] and one nested case-control study[@ref112] reported adjusted data. The retrospective cohort study, including 13 185 patients and with a median follow-up of four years, suggested that, compared with sulfonylureas, DPP-4 inhibitors was statistically associated with an increased risk of congestive heart failure (adjusted hazard ratio 1.10, 95% confidence interval 1.04 to 1.17). The nested case-control study, selecting 457 heart failure cases and 4570 controls, showed no statistical difference in the risk of heart failure between use and no use of sitagliptinin the 90 days before acute coronary syndrome (adjusted odds ratio 0.75, 95% confidence interval 0.38 to 1.46, table 5[](#tbl5){ref-type="table"}). Using GRADE, we rated the quality of evidence in the identified studies as very low, owing to risk of bias, indirectness, and imprecision in addition to the inherent risk for confounding given the observational design.

### Observational studies reporting hospital admission for heart failure

Of the eight studies reporting hospital admission for heart failure, six retrospective cohort studies,[@ref13] [@ref14] [@ref15] [@ref113] [@ref114] [@ref115] using registry data, claims data, or electronic medical records, assessed DPP-4 inhibitors versus active drugs (eg, sulfonylureas, pioglitazone), and the use of sitagliptin versus no use of sitagliptin. The other two nested case-control studies[@ref16] [@ref17] assessed use of sitagliptin versus no use of sitagliptin, and incretin based drugs (including the DPP-4 inhibitors subgroup) versus other oral antidiabetic drugs (tables 4 and 5[](#tbl4 tbl5){ref-type="table"}). The sample sizes of these eight studies ranged from 4224 to 935 519, and the mean or median length of follow-up ranged from 0.5 to 2.6 years. Enrolled patients had a mean age ranging from 54.6 to 67 years, mean baseline HbA1c level ranging from 7.5% to 8.0%, and a mean duration of diabetes ranging from 2.3 to 8.6 years.

The eight studies used registry data, claims data, or electronic medical records for analyses. Only two studies[@ref15] [@ref113] explicitly reported use of ICD codes to ascertain patients with diabetes; one study[@ref13] ascertained exposure to DPP-4 inhibitors by using anatomical therapeutic chemical classes; three studies[@ref13] [@ref15] [@ref113] explicitly stated use of ICD codes to ascertain other confounding variables. Four studies[@ref13] [@ref15] [@ref113] [@ref114] used ICD-9 or ICD-10 codes to assess outcomes. Three cohort studies[@ref13] [@ref113] [@ref114] clarified that the outcome of interest was not present at enrolment. All eight studies controlled for potential confounding factors, but failed to specify the extent to which the data were complete in the database (web appendices 4 and 5).

### Effects on hospital admission for heart failure

All but one retrospective cohort study[@ref115] reported unadjusted rates of hospital admission for heart failure. The five cohort studies[@ref13] [@ref14] [@ref15] [@ref113] [@ref114] included 3500 events among 1 630 884 patients (raw event rate 0.2%; 1466 events (0.2%) in 912 309 patients from the DPP-4 inhibitors group, and 2034 events (0.3%) in 718 575 patients from the control group). The two nested case-control studies[@ref16] [@ref17] involved 1942 cases among 27 806 patients. Because of the variety of confounding factors investigated in the studies, we did not pool the unadjusted data.

All eight studies reported adjusted estimates of hospital admission for heart failure. Of these, six studies---five cohort studies and one nested case-control study---compared DPP-4 inhibitors with active drugs (sulfonylureas, pioglitazone, other oral antidiabetic drugs). Pooling of adjusted estimates from these six studies showed that DPP-4 inhibitors were associated with reduced risk of hospital admission for heart failure (adjusted odds ratio 0.85, 95% confidence interval 0.74 to 0.97; I^2^=31%). However, pooling of the cohort study[@ref15] (16 576 patients and 614 events), and the nested case-control study[@ref16] (824 cases and 8238 controls) suggested a non-significant trend for increased risk of admission for heart failure compared with no use of sitagliptin (adjusted odds ratio 1.41, 0.95 to 2.09; I^2^=65%). There was significant subgroup effect by type of control (interaction P=0.02, fig 4[](#f4){ref-type="fig"}). Using GRADE, we rated the quality of evidence as very low, due to risk of bias, heterogeneity, and imprecision in addition to the inherent risk for confounding given the observational design.

![**Fig 4** Risk of hospital admission for heart failure in patients with type 2 diabetes who received DPP-4 inhibitors versus control based on adjusted data from observational studies. SE=standard error; IV=inverse variance](lili029738.f4_default){#f4}

Table 6[](#tbl6){ref-type="table"} summarises the evidence regarding the effects of DPP-4 inhibitors on heart failure or hospital admission for heart failure.

###### 

Risk of heart failure or hospital admission for heart failure among patients with type 2 diabetes receiving DPP-4 inhibitor treatment

  Comparison                                                No of studies (events or cases, patients)   DPP-4 inhibitors (events/patients)   Control (events/patients)   Effect estimate (95%CI)                  Cardiovascular morbidities at baseline
  --------------------------------------------------------- ------------------------------------------- ------------------------------------ --------------------------- ---------------------------------------- ------------------------------------------------------------
  **Heart failure**                                                                                                                                                                                               
  Randomised controlled trials                                                                                                                                                                                    
   DPP-4 inhibitors *v* control                             38 (75, 28 292)                             42/15 701                            33/12 591                   Pooled OR 0.97 (0.61 to 1.56)            Typically without CVD
  Observational studies                                                                                                                                                                                           
   DPP-4 inhibitors *v* SU                                  1 (11, 616)                                 8/436                                3/153                       Unadjusted OR 0.88 (0.22 to 3.48)        With or without CVD
   DPP-4 inhibitors *v* SU                                  1 (528, 13 185)                             NR                                   NR                          Adjusted HR 1.10 (1.04 to 1.17)          No history of CVD or congestive heart failure
   Sitagliptin *v* SU                                       1 (2, 2607)                                 1/1874                               1/733                       Unadjusted OR 0.39 (0.02 to 6.26)        NR
   Sitagliptin use *v* no use                               1 (457, 5027)                               ---                                  ---                         Adjusted OR 0.75 (0.38 to 1.46)          Admission to hospital for an acute coronary syndrome event
  **Hospital admission for heart failure**                                                                                                                                                                        
  Randomised controlled trials                                                                                                                                                                                    
   DPP-4 inhibitors *v* control                             5 (1174, 37 028)                            622/18 554                           522/18 474                  Pooled OR 1.13 (1.00 to 1.26)            CVD or multiple risk factors for vascular disease
  Observational studies                                                                                                                                                                                           
   DPP-4 inhibitors *v* active control (pooled estimates)   6 (4341, 1 618 295)                         ---                                  ---                         Pooled adjusted OR 0.85 (0.74 to 0.97)   With or without CVD
   DPP-4 inhibitors *v* SU                                  3 (1875, 657 596)                           380/202 292                          1495/455 304                Adjusted HR 0.84 (0.74 to 0.96)          With or without CVD
   DPP-4 inhibitors *v* pioglitazone                        2 (1060, 1 031 432)                         796/776 449                          264/254 983                 Adjusted HR 0.67 (0.57 to 0.78)          With or without CVD
   DPP-4 inhibitors *v* other OADs                          1 (1118, 18 744)\*                                                                                           Adjusted OR 0.88 (0.63 to 1.22)          With or without CVD
   DPP-4 inhibitors *v* control                             1 (127, 3987)                               NR                                   NR                          Adjusted HR 0.58 (0.38, 0.88)            With or without CVD
   Sitagliptin use *v* no use (pooled estimates)            2 (1438, 25 638)                            ---                                  ---                         Pooled adjusted OR 1.41 (0.95 to 2.09)   ---
   Sitagliptin use *v* no use                               1 (614, 16 576)                             339/8288                             275/8288                    Adjusted HR 1.21 (1.04 to 1.42)          With or without CVD
   Sitagliptin use *v* no use                               1 (824, 9062)\*                                                                                              Adjusted OR 1.84 (1.16 to 2.92)          Heart failure at baseline

CVD=cardiovascular disease; SU=sulfonylurea; OR=odds ratio; HR=hazard ratio; NR=not reported; OADs=oral antidiabetic drugs.

\*Nested case-control study.

Discussion
==========

Main findings
-------------

The only evidence of moderate quality from our results is from randomised controlled trials that examined the effect of DPP-4 inhibitors on hospital admission for heart failure. These studies suggested a small increase, in both relative and absolute terms, in heart failure admissions in patients using DPP-4 inhibitors than those not. The results, however, are of borderline significance. Evidence from observational studies is of very low quality, and thus has little bearing on any inferences about DPP-4 inhibitor effects on heart failure admission.

With respect to the incidence of heart failure, trial evidence leaves uncertainty regarding the relative effect of DPP-4 inhibitors. Because the follow-up was relatively short and the baseline risk of patients was very low in those trials, the incidence of heart failure was very low (well under 1% per year), and with the small number of events, the confidence intervals around relative effects are wide. In addition, heart failure was unspecified in all but one of the phase III trials. Many (87%) reported heart failure as serious adverse events, in which admission for heart failure might have been included according to the definition of serious adverse events. The pooled estimate could thus represent a composite of heart failure with or without admission for heart failure. The observational studies again provide very low quality evidence and have little effect on inferences, although results are consistent. Overall, the current evidence provides no support for the hypothesis that DPP-4 inhibitors increase the incidence of heart failure.

Strengths and limitations
-------------------------

Our study has several strengths. Firstly, we used rigorous methods to systematically identify and include data from both randomised and non-randomised studies to examine the effect of DPP-4 inhibitors on risk of heart failure and hospital admission for heart failure. Secondly, in addition to published reports, we have identified additional data from ClinicalTrials.gov. Our study included four randomised controlled trials and three observational studies that were not published in journals. Thirdly, we instituted a rigorous approach to ensure the data were accurate. In particular, we carefully checked the data reported in ClinicalTrials.gov and journal publications for consistency. Fourthly, we addressed several prespecified subgroup analyses to explore sources of heterogeneity. Finally, we used GRADE to assess the quality of the body of evidence.

Our study also had some limitations. Firstly, for various reasons, some trials are likely not to report outcome data in their full publications. However, we have obtained additional data through the search of the ClinicalTrials.gov and conference abstracts, which minimised the risk of outcome reporting bias. Secondly, given the limitations of reported data, we were unable to confirm whether the increased risk of hospital admission for heart failure was a class effect or a specific effect of saxagliptin. Other limitations included those of the primary studies, such as the risk of bias of observational studies, the potentially variable specification of outcomes (heart failure and hospital admission for heart failure), and the likelihood of variable and incomplete ascertainment of heart failure in the clinical trials.

Comparison with other studies
-----------------------------

Four previous meta-analyses[@ref7] [@ref117] [@ref118] [@ref119] have explored the effect of DPP-4 inhibitors on the risk of heart failure. Of those studies, one[@ref7] found that treatment with DPP-4 inhibitors for 29 weeks or longer was associated with an increased risk of new onset of heart failure (risk ratio 1.16, 95% confidence interval 1.01 to 1.33), but not with treatment for less than 29 weeks (0.67, 0.32 to 1.40). The second[@ref117] included 24 randomised controlled trials that enrolled no less than 100 patients and followed up patients for 24 weeks; the third[@ref118] exclusively included 37 trials for analysis; the fourth[@ref119] included trials and observational studies. All the last three studies found that DPP-4 inhibitors were statistically associated with an increased risk of heart failure (risk ratio 1.16 (1.01 to 1.33), odds ratio 1.19 (1.03 to 1.37), odds ratio 1.15 (1.02 to 1.29), respectively).

Compared with these studies, our review has added substantial information. Firstly, we separately addressed heart failure and hospital admission as a result of heart failure. Secondly, we included both observational studies and randomised controlled trials. With respect to the trials, two important large trials[@ref11] [@ref12] were published subsequent to the previous reviews and allowed us to analyse the effect of DPP-4 inhibitors on hospital admission for heart failure. We also included additional large observational studies that carry important information regarding the risk of heart failure or admission for heart failure.

Our findings regarding the effect of DPP-4 inhibitors on heart failure were not consistent with previous meta-analyses. This difference is probably due to the fact that the previous studies were dominated by large trials reporting positive association with hospital admission for heart failure (eg, SAVOR TIMI-53), and more recent trials that have failed to find an effect were not considered.

We also found all four meta-analyses in our study[@ref7] [@ref117] [@ref118] [@ref119] to have several methodological issues. Firstly, these reviews have pooled data for heart failure and hospital admissions for heart failure. We believe that a more appropriate analysis should consider the two outcomes separately. We identified varying results when analysing the two outcomes separately. More importantly, the pooling of the two outcomes together would probably result in misleading effect estimates, when the authors aimed to assess the effect of DPP-4 inhibitors on the risk of heart failure. Another meta-analysis[@ref7] investigated DPP-4 inhibitors on the risk of new onset of heart failure, but this study included trials, such as SAVOR TIMI-53 and EXAMINE that already included patients with heart failure at baseline. The third meta-analysis[@ref117] failed to include outcome data published in ClinicalTrials.gov. The final meta-analysis[@ref119] combined randomised controlled trials and observational studies to generate grand effect estimates. Because of the substantial differences in the design and analysis of the type of studies, and the considerable variation in observational studies, the grand pooling will introduce misleading findings.

Implications for practice
-------------------------

The current evidence suggests a possible increased risk of hospital admission for heart failure in those patients with type 2 diabetes treated with DPP-4 inhibitors and with cardiovascular diseases or multiple risk factors for vascular diseases at baseline. Although the effect is small if it exists, and the associated confidence interval includes no effect, our results suggest the advisability of caution in the use of DPP-4 inhibitors for patients with type 2 diabetes who are at high risk for heart failure.

Conclusions
-----------

The relative effect of DPP-4 inhibitors on heart failure remains uncertain in patients with type 2 diabetes, given the relatively short follow-up and low quality of evidence. The current evidence suggests a small increase in the risk of hospital admission for heart failure in patients with existing cardiovascular diseases or multiple risk factors for vascular diseases. Additional randomised controlled trials enrolling patients with existing cardiovascular diseases or multiple risk factors for vascular diseases will be required to definitively assess the effect of DPP-4 inhibitors on such patients. Such trials, if enrolling patients at high risk of exacerbation and admission, may be feasible. In the meantime, the possible increase in hospital admission for heart failure could be one issue that patients and clinicians consider in choosing antidiabetic drug treatment for patients with existing cardiovascular diseases.

### What is already known on this topic

1.  Several occurrences of heart failure or hospital admission for heart failure have been reported in patients with type 2 diabetes taking DPP-4 inhibitors

2.  Systematic reviews of randomised controlled trials and observational studies have suggested an increased risk of heart failure or admission for heart failure associated with the agents

### What this study adds

1.  The relative effect of DPP-4 inhibitors on the risk of heart failure is uncertain

2.  Current evidence from trials and observational studies suggests a small increase in risk of admission for heart failure in patients with type 2 diabetes who have existing cardiovascular diseases or multiple risk factors for vascular diseases, relative to no use
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